Publications

The impact of local vaccine coverage and recent incidence on measles transmission in France between 2009 and 2018.

ROBERT, A; KUCHARSKI, AJ; FUNK, S;

2022

BMC Medicine, (2022).20 1 10.1186/s12916-022-02277-5.

Mathematical Modelling for Optimal Vaccine Dose Finding: Maximising Efficacy and Minimising Toxicity.

BENEST, J; Rhodes, S; Evans, TG; WHITE, RG;

2022

Vaccines, (2022).10 5 10.3390/vaccines10050756.

Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.

Rhodes, S; Smith, N; Evans, T; WHITE, R;

2022

Vaccine, (2022).40 49 10.1016/j.vaccine.2022.10.012.

Public health and social measures to mitigate the health and economic impact of the COVID-19 pandemic in Turkey, Egypt, Ukraine, Kazakhstan, and Poland during 2020-2021: situational analysis.

KITAMURA, N; ABBAS, K; Nathwani, D;

2022

BMC public health, (2022).22 1 10.1186/s12889-022-13411-6.

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

WATSON-JONES, D; Kavunga-Membo, H; Grais, RF; Ahuka, S; Roberts, N; EDMUNDS, WJ; CHOI, EM; ROBERTS, CH; EDWARDS, T; Camacho, A; LEES, S; Leyssen, M; Spiessens, B; Luhn, K; Douoguih, M; Hatchett, R; Bausch, DG; Muyembe, J-J; DRC-EB-001 protocol writing team,;

2022

BMJ open, (2022).12 3 10.1136/bmjopen-2021-055596.

Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study.

Kim, C; Holm, M; Frost, I; Hasso-Agopsowicz, M; Abbas, K;

2022

medRxiv (2022). 10.1101/2022.05.08.22274821.

Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel.

Miner, MD; Hatherill, M; Mave, V; Gray, GE; Nachman, S; Read, SW; WHITE, RG; Hesseling, A; Cobelens, F; Patel, S; Frick, M; Bailey, T; Seder, R; Flynn, J; Rengarajan, J; Kaushal, D; Hanekom, W; Schmidt, AC; Scriba, TJ; Nemes, E; Andersen-Nissen, E; Landay, A; Dorman, SE; Aldrovandi, G; Cranmer, LM; ... Churchyard, G.

2022

The lancet. HIV, (2022).9 11 10.1016/S2352-3018(22)00255-7.

Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?.

PARKER, EP K; Desai, S; Marti, M; O'Brien, KL; Kaslow, DC; Kochhar, S; Olayinka, F; Cravioto, A; Nohynek, H; Hombach, J; Wilder-Smith, A;

2022

The Lancet Infectious Diseases, (2022).22 4 10.1016/S1473-3099(22)00178-5.

COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.

Toor, J; Li, X; JIT, M; Trotter, CL; Echeverria-Londono, S; Hartner, A-M; Roth, J; Portnoy, A; ABBAS, K; Ferguson, NM; Am Gaythorpe, K;

2022

Vaccine, (2022).40 31 10.1016/j.vaccine.2022.05.074.

WHO-led consensus statement on vaccine delivery costing: process, methods, and findings.

Levin, A; Boonstoppel, L; Brenzel, L; Griffiths, U; Hutubessy, R; JIT, M; Mogasale, V; Pallas, S; Resch, S; Suharlim, C; Yeung, KH T;